Lycopene used as Anti-inflammatory Nanodrug for the Treatment of Rheumathoid Arthritis: Animal assay, Pharmacokinetics, ABC Transporter and Tissue Deposition

Vivian Meira Moia; Filipe Leal Portilho; Tatiana Almeida Pádua; Luana Barbosa Corrêa; Eduardo Ricci-Junior; Elaine Cruz Rosas; Luiciana Magalhaes Rebelo Alencar; Francisco Savio Mendes Sinfronio; Angelina Sampson; Surtaj Hussain Iram; Frank Alexis; Maria das Graccedilas Muller de OliveiraHenriques; Ralph Santos-Oliveira

doi:10.1016/j.colsurfb.2020.110814

Lycopene used as Anti-inflammatory Nanodrug for the Treatment of Rheumathoid Arthritis: Animal assay, Pharmacokinetics, ABC Transporter and Tissue Deposition

Vivian Meira Moia
, Filipe Leal Portilho
, Tatiana Almeida Pádua
, Luana Barbosa Corrêa
, Eduardo Ricci-Junior
, Elaine Cruz Rosas
, Luiciana Magalhaes Rebelo Alencar
, Francisco Savio Mendes Sinfronio
, Angelina Sampson
, Surtaj Hussain Iram
, Frank Alexis
, Maria das Graccedilas Muller de OliveiraHenriques
, Ralph Santos-Oliveira^*

^*Corresponding author for this work

Nuclear Engineering Institute
Fundação Oswaldo Cruz
Museu Nacional/UFRJ
Federal University of Maranhão
South Dakota State University
Universidad Yachay Tech
Universidade do Estado do Rio de Janeiro

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Lycopene is a carotenoid drug that has demonstrated several properties, including antioxidant and anti-inflammatory activity. The absorption in human body is very low (10–30 % only). In order to increase the bioavailability, lycopene nanoemulsion was formulated and characterized (atomic force microscopy, thermogravimetric analysis dynamic light scattering and differential scanning calorimetry). Also in vitro assay to evaluate the at-binding with MPR1 was performed. Finally, in vivo assay in animals inducted with rheumathoid arthritis were performed. The results showed that the formulated nanolycopene had superior efficacy when compared with the conventional lycopene (not nano-formulated) in inducted animals (rheumatoid arthritis). The results support the use of nanolycopene as an anti-inflammatory agent for rheumatoid arthritis therapy.

Original language	English
Article number	110814
Journal	Colloids and Surfaces B: Biointerfaces
Volume	188
DOIs	https://doi.org/10.1016/j.colsurfb.2020.110814
State	Published - Apr 2020
Externally published	Yes

Keywords

Anti-Inflammatory
Arthritis
Drug
Drug resistance
Nanotechnology

Access to Document

10.1016/j.colsurfb.2020.110814

Cite this

Moia, V. M., Leal Portilho, F., Almeida Pádua, T., Barbosa Corrêa, L., Ricci-Junior, E., Cruz Rosas, E., Magalhaes Rebelo Alencar, L., Savio Mendes Sinfronio, F., Sampson, A., Hussain Iram, S., Alexis, F., de OliveiraHenriques, M. D. G. M., & Santos-Oliveira, R. (2020). Lycopene used as Anti-inflammatory Nanodrug for the Treatment of Rheumathoid Arthritis: Animal assay, Pharmacokinetics, ABC Transporter and Tissue Deposition. Colloids and Surfaces B: Biointerfaces, 188, Article 110814. https://doi.org/10.1016/j.colsurfb.2020.110814

@article{72bbb4af2d734392b4552b42d9e038d4,

title = "Lycopene used as Anti-inflammatory Nanodrug for the Treatment of Rheumathoid Arthritis: Animal assay, Pharmacokinetics, ABC Transporter and Tissue Deposition",

abstract = "Lycopene is a carotenoid drug that has demonstrated several properties, including antioxidant and anti-inflammatory activity. The absorption in human body is very low (10–30 \% only). In order to increase the bioavailability, lycopene nanoemulsion was formulated and characterized (atomic force microscopy, thermogravimetric analysis dynamic light scattering and differential scanning calorimetry). Also in vitro assay to evaluate the at-binding with MPR1 was performed. Finally, in vivo assay in animals inducted with rheumathoid arthritis were performed. The results showed that the formulated nanolycopene had superior efficacy when compared with the conventional lycopene (not nano-formulated) in inducted animals (rheumatoid arthritis). The results support the use of nanolycopene as an anti-inflammatory agent for rheumatoid arthritis therapy.",

keywords = "Anti-Inflammatory, Arthritis, Drug, Drug resistance, Nanotechnology",

author = "Moia, \{Vivian Meira\} and \{Leal Portilho\}, Filipe and \{Almeida P{\'a}dua\}, Tatiana and \{Barbosa Corr{\^e}a\}, Luana and Eduardo Ricci-Junior and \{Cruz Rosas\}, Elaine and \{Magalhaes Rebelo Alencar\}, Luiciana and \{Savio Mendes Sinfronio\}, Francisco and Angelina Sampson and \{Hussain Iram\}, Surtaj and Frank Alexis and \{de OliveiraHenriques\}, \{Maria das Graccedilas Muller\} and Ralph Santos-Oliveira",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier B.V.",

year = "2020",

month = apr,

doi = "10.1016/j.colsurfb.2020.110814",

language = "Ingl{\'e}s",

volume = "188",

journal = "Colloids and Surfaces B: Biointerfaces",

issn = "0927-7765",

publisher = "Elsevier B.V.",

}

Moia, VM, Leal Portilho, F, Almeida Pádua, T, Barbosa Corrêa, L, Ricci-Junior, E, Cruz Rosas, E, Magalhaes Rebelo Alencar, L, Savio Mendes Sinfronio, F, Sampson, A, Hussain Iram, S, Alexis, F, de OliveiraHenriques, MDGM & Santos-Oliveira, R 2020, 'Lycopene used as Anti-inflammatory Nanodrug for the Treatment of Rheumathoid Arthritis: Animal assay, Pharmacokinetics, ABC Transporter and Tissue Deposition', Colloids and Surfaces B: Biointerfaces, vol. 188, 110814. https://doi.org/10.1016/j.colsurfb.2020.110814

Lycopene used as Anti-inflammatory Nanodrug for the Treatment of Rheumathoid Arthritis: Animal assay, Pharmacokinetics, ABC Transporter and Tissue Deposition. / Moia, Vivian Meira; Leal Portilho, Filipe; Almeida Pádua, Tatiana et al.
In: Colloids and Surfaces B: Biointerfaces, Vol. 188, 110814, 04.2020.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Lycopene used as Anti-inflammatory Nanodrug for the Treatment of Rheumathoid Arthritis

T2 - Animal assay, Pharmacokinetics, ABC Transporter and Tissue Deposition

AU - Moia, Vivian Meira

AU - Leal Portilho, Filipe

AU - Almeida Pádua, Tatiana

AU - Barbosa Corrêa, Luana

AU - Ricci-Junior, Eduardo

AU - Cruz Rosas, Elaine

AU - Magalhaes Rebelo Alencar, Luiciana

AU - Savio Mendes Sinfronio, Francisco

AU - Sampson, Angelina

AU - Hussain Iram, Surtaj

AU - Alexis, Frank

AU - de OliveiraHenriques, Maria das Graccedilas Muller

AU - Santos-Oliveira, Ralph

PY - 2020/4

Y1 - 2020/4

N2 - Lycopene is a carotenoid drug that has demonstrated several properties, including antioxidant and anti-inflammatory activity. The absorption in human body is very low (10–30 % only). In order to increase the bioavailability, lycopene nanoemulsion was formulated and characterized (atomic force microscopy, thermogravimetric analysis dynamic light scattering and differential scanning calorimetry). Also in vitro assay to evaluate the at-binding with MPR1 was performed. Finally, in vivo assay in animals inducted with rheumathoid arthritis were performed. The results showed that the formulated nanolycopene had superior efficacy when compared with the conventional lycopene (not nano-formulated) in inducted animals (rheumatoid arthritis). The results support the use of nanolycopene as an anti-inflammatory agent for rheumatoid arthritis therapy.

AB - Lycopene is a carotenoid drug that has demonstrated several properties, including antioxidant and anti-inflammatory activity. The absorption in human body is very low (10–30 % only). In order to increase the bioavailability, lycopene nanoemulsion was formulated and characterized (atomic force microscopy, thermogravimetric analysis dynamic light scattering and differential scanning calorimetry). Also in vitro assay to evaluate the at-binding with MPR1 was performed. Finally, in vivo assay in animals inducted with rheumathoid arthritis were performed. The results showed that the formulated nanolycopene had superior efficacy when compared with the conventional lycopene (not nano-formulated) in inducted animals (rheumatoid arthritis). The results support the use of nanolycopene as an anti-inflammatory agent for rheumatoid arthritis therapy.

KW - Anti-Inflammatory

KW - Arthritis

KW - Drug

KW - Drug resistance

KW - Nanotechnology

UR - https://www.scopus.com/pages/publications/85078180163

U2 - 10.1016/j.colsurfb.2020.110814

DO - 10.1016/j.colsurfb.2020.110814

M3 - Artículo

C2 - 31982791

AN - SCOPUS:85078180163

SN - 0927-7765

VL - 188

JO - Colloids and Surfaces B: Biointerfaces

JF - Colloids and Surfaces B: Biointerfaces

M1 - 110814

ER -

Lycopene used as Anti-inflammatory Nanodrug for the Treatment of Rheumathoid Arthritis: Animal assay, Pharmacokinetics, ABC Transporter and Tissue Deposition

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this